Phase 1 Study of Tumor Treating Fields with Cabozantinib or With Nab-Paclitaxel and Atezolizumab in Adults with Advanced Solid Tumors in the Abdomen or Thorax

What this Trial Is About

Researchers are evaluating a phase Ib trial to test the safety, side effects, and best dose of tumor treating fields TTF therapy combined with either cabozantinib or with nab-paclitaxel and atezolizumab in patients with advanced solid tumors involving the abdomen or thorax. These tumors have spread to other parts of the body, and the study focuses on four specific tumor types. TTF uses wearable devices that apply electrical fields to potentially stop tumor cells from dividing, while cabozantinib, nab-paclitaxel, and atezolizumab work in different ways to target tumor growth and spread. Participants are assigned to one of two treatment groups. In Cohort 1, patients receive continuous TTF therapy for at least 18 hours daily on days 1 to 21 of each 21-day cycle along with daily oral cabozantinib. In Cohort 2, patients receive continuous TTF therapy for at least 18 hours daily on days 1 to 28 of each 28-day cycle, combined with intravenous nab-paclitaxel on days 1, 8, and 15, and intravenous atezolizumab on days 1 and 15. Treatment continues in cycles until disease progression or unacceptable side effects occur. During the study, participants are monitored for safety, side effects, and tumor response. After completing treatment, patients are followed for six weeks. Researchers assess safety and tolerability, including the maximum tolerated dose of TTF combined with the medications, as well as objective response rates, progression-free survival, and overall survival. The total study duration includes treatment cycles followed by this follow-up period to evaluate outcomes and any ongoing effects.

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax